ALKERMES | ALKS - Stock


ALKERMES reported $191M in Stock for its fiscal quarter ending in September of 2025.





Stock Change Date
AbbVie USD 4.95B 13M Dec/2025
Acadia Pharmaceuticals USD 29.1M 2.97M Sep/2025
ALKERMES USD 191M 927K Sep/2025
Amgen USD 6.22B 121M Dec/2025
Biogen USD 2.17B 41.3M Dec/2025
BioMarin Pharmaceutical USD 1.3B 83.29M Dec/2025
Bristol-Myers Squibb USD 2.76B 21M Sep/2025
Coherus Biosciences USD 2.05M 2.46M Sep/2025
Eli Lilly USD 13.74B 1.56B Dec/2025
Gilead Sciences USD 1.78B 40M Sep/2025
Heron Therapeutics USD 54.57M 2.33M Dec/2022
Ionis Pharmaceuticals USD 10.47M 1.99M Sep/2025
J&J USD 14.19B 45M Dec/2025
Merck USD 6.44B 157M Sep/2025
Nektar Therapeutics USD 14.46M 1.78M Jun/2024
Neurocrine Biosciences USD 69M 300K Dec/2025
Otsuka Holdings JPY 350.53B 42.43B Jun/2025
Pfizer USD 11.47B 201M Sep/2025
Regeneron Pharmaceuticals USD 3.2B 53.6M Dec/2025
Vertex Pharmaceuticals USD 1.69B 60M Dec/2025